Extended collaboration with Recordati in Spain

Extended collaboration with Recordati in Spain

Meda has extended its collaboration with the Italian pharma company Recordati in
the cardiovascular area. A long-term agreement has been signed for Lercadip®
(lercanidipine) in Spain. The product is a calcium antagonist indicated for
treatment of high blood pressure. Meda takes over an existing annual turnover of
about 60 MSEK from a previous licensee. Under the agreement, Meda has undertaken
to pay milestones equivalent to approximately one times annual sales. 

In Spain, Meda already holds marketing rights to the combination product
Coripren®, lercanidipine + enalapril (a well-known ACE inhibitor). This product
is intended to be launched during 2009.  Marketing synergies are expected with
Lercadip.


For more information, please contact:

Anders Larnholt, Vice President Investor Relations, tel. +46 709 458 878


MEDA AB (publ) is a leading international specialty pharma company. The company
specialises in marketing and pharmaceutical development in late clinical stage.
Acquisitions and long-term partnerships are fundamental factors that drive the
company's strategy. Meda is represented by its own organisations in about 40
countries. Meda's products are sold in 120 countries worldwide. The Meda share
is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit
www.meda.se.